Efficacy and Safety of Vonoprazan versus PPIs in Treating Reflux Esophagitis:a Meta-analysis
1.The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine,Shenzhen 518033,China
2.Department of Spleen and Stomach,Shenzhen Traditional Chinese Medicine Hospital,Shenzhen 518033,China
*Corresponding author:HUANG Bin,Chief TCM physician;E-mail:1677825889@qq.com
LI Mianli,ZHANG Weijian,GUO Linglong, et al. Efficacy and Safety of Vonoprazan versus PPIs in Treating Reflux Esophagitis:a Meta-analysis [J]. Chinese General Practice, 2021, 24(6): 712-717. DOI: 10.12114/j.issn.1007-9572.2020.00.621.
李勉力,张伟健,郭玲珑等. 沃诺拉赞对比质子泵抑制剂治疗反流性食管炎有效性和安全性的Meta分析[J]. 中国全科医学, 2021, 24(6): 712-717. DOI: 10.12114/j.issn.1007-9572.2020.00.621.
[1]LUNDELL L R,DENT J,BENNETT J R,et al.Endoscopic assessment of oesophagitis:clinical and functional correlates and further validation of the Los Angeles classification[J].Gut,1999,45(2):172-180.DOI:10.1136/gut.45.2.172.
[2]ZOU D W,HE J,MA X Q,et al.Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis:the systematic investigation of gastrointestinal diseases in China (SILC)[J].Scand J Gastroenterol,2011,46(2):133-141.DOI:10.3109/00365521.2010.521888.
[3]RONKAINEN J,ARO P,STORSKRUBB T,et al.High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population:a Kalixanda study report[J].Scand J Gastroenterol,2005,40(3):275-285.DOI:10.1080/00365520510011579.
[4]ZAGARI R M,FUCCIO L,WALLANDER M A,et al.Gastro-oesophageal reflux symptoms,oesophagitis and Barrett's oesophagus in the general population:the Loiano-Monghidoro study[J].Gut,2008,57(10):1354-1359.DOI:10.1136/gut.2007.145177.
[5]REVICKI D A,WOOD M,MATON P N,et al.The impact of gastroesophageal reflux disease on health-related quality of life[J].Am J Med,1998,104(3):252-258.DOI:10.1016/s0002-9343(97)00354-9.
[6]RICHTER J E,RUBENSTEIN J H.Presentation and epidemiology of gastroesophageal reflux disease[J].Gastroenterology,2018,154(2):267-276.DOI:10.1053/j.gastro.2017.07.045.
[7]SACHS G,SHIN J M,HOWDEN C W.Review article:the clinical pharmacology of proton pump inhibitors[J].Aliment Pharmacol Ther,2006,23(Suppl 2):2-8.DOI:10.1111/j.1365-2036.2006.02943.x.
[8]HORI Y,IMANISHI A,MATSUKAWA J,et al.1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438),a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases[J].J Pharmacol Exp Ther,2010,335(1):231-238.DOI:10.1124/jpet.110.170274.
[9]HORI Y,MATSUKAWA J,TAKEUCHI T,et al.A study comparing the antisecretory effect of TAK-438,a novel potassium-competitive acid blocker,with lansoprazole in animals[J].J Pharmacol Exp Ther,2011,337(3):797-804.DOI:10.1124/jpet.111.179556.
[10]XIAO Y L,ZHANG S T,DAI N,et al.Phase Ⅲ,randomised,double-blind,multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis[J].Gut,2020,69(2):224-230.DOI:10.1136/gutjnl-2019-318365.
[11]UEMURA N,KINOSHITA Y,HARUMA K,et al.1-year interim analysis results of vision trial:a randomized,open-label study to evaluate a long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis[J].Gastroenterology,2019,156(6):S-302-S-303.DOI:10.1016/s0016-5085(19)37576-6.
[12]SAKURAI K,SUDA H,FUJIE S,et al.Short-term symptomatic relief in gastroesophageal reflux disease:a comparative study of esomeprazole and vonoprazan[J].Dig Dis Sci,2019,64(3):815-822.DOI:10.1007/s10620-018-5365-0.
[13]ASHIDA K,SAKURAI Y,HORI T,et al.Randomised clinical trial:vonoprazan,a novel potassium-competitive acid blocker,vs.lansoprazole for the healing of erosive oesophagitis[J].Aliment Pharmacol Ther,2016,43(2):240-251.DOI:10.1111/apt.13461.
[14]ASHIDA K,SAKURAI Y,NISHIMURA A,et al.Randomised clinical trial:a dose-ranging study of vonoprazan,a novel potassium-competitive acid blocker,vs.lansoprazole for the treatment of erosive oesophagitis[J].Aliment Pharmacol Ther,2015,42(6):685-695.DOI:10.1111/apt.13331.
[15]GREMSE D,GOLD B D,PILMER B,et al.Dual delayed-release dexlansoprazole for healing and maintenance of healed erosive esophagitis:a safety study in adolescents[J].Dig Dis Sci,2019,64(2):493-502.DOI:10.1007/s10620-018-5325-8.
[16]POELMANS J,TACK J,FEENSTRA L.Chronic middle ear disease and gastroesophageal reflux disease:a causal relation?[J].Otol Neurotol,2001,22(4):447-450.DOI:10.1097/00129492-200107000-00005.
[17]YANG X X,LI Y Y,SUN Y Y,et al.Vonoprazan:a novel and potent alternative in the treatment of acid-related diseases[J].Dig Dis Sci,2018,63(2):302-311.DOI:10.1007/s10620-017-4866-6.
[18]BELL N J,HUNT R H.Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease[J].Gut,1992,33(1):118-124.DOI:10.1136/gut.33.1.118.
[19]YUAN Y,HUNT R H.PWE-078 Intragastric ph holding time of pH <4 predicts low erosive esophagitis healing rate[J].Gut,2010,59(Suppl 1):A116.2-A116.DOI:10.1136/gut.2009.208983v.
[20]IWAKIRI K,SAKURAI Y,SHIINO M,et al.A randomized,double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis[J].Therap Adv Gastroenterol,2017,10(6):439-451.DOI:10.1177/1756283X17705329.
[21]HUNT R H,ARMSTRONG D,JAMES C,et al.Effect on intragastric pH of a PPI with a prolonged plasma half-life:comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers[J].Am J Gastroenterol,2005,100(9):1949-1956.DOI:10.1111/j.1572-0241.2005.41956.x.
[22]JENKINS H,SAKURAI Y,NISHIMURA A,et al.Randomised clinical trial:safety,tolerability,pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan),a novel potassium-competitive acid blocker,in healthy male subjects[J].Aliment Pharmacol Ther,2015,41(7):636-648.DOI:10.1111/apt.13121.
[23]CHENG Y,LIU J L,TAN X,et al.Direct comparison of the efficacy and safety of vonoprazan versus proton-pump inhibitors for gastroesophageal reflux disease:a systematic review and meta-analysis[J].Dig Dis Sci,2020.DOI:10.1007/s10620-020-06141-5.